Hufeng Zhou

The multiomic Variant-to-Gene (mV2G; https://mv2g.hbliulab.org) is a comprehensive atlas that integrates diverse functional genomic evidence to prioritize tissue-specific variant-to-gene (V2G) associations. While genome-wide association studies (GWAS) have identified millions of associations between genetic variants and diseases, translating these findings into biological mechanisms remains challenging because >90% of variants reside in noncoding regions. Existing V2G resources provide complementary regulatory evidence but are fragmented and often lack tissue-specific interpretation. To address this challenge, we constructed the mV2G atlas by integrating 24 types of functional genomic evidence across 50 human tissues, including molecular quantitative trait loci, enhancer–gene predictions, 3D chromatin interactions, and experimental validation. The atlas contains 188 634 118 evidence-supported V2G pairs involving 13 618 039 variants and 69 521 genes. To prioritize high-confidence V2G pairs, we developed a CRISPR-informed, evidence-weighted model. Using this model, we prioritized 3 348 174 high-confidence V2G pairs, 88% of which were tissue-specific. The mV2G atlas provides searchable variant- and gene-centered interfaces, an interactive browser for visualizing variants, target genes, cis-regulatory elements, and chromatin states, as well as downloadable datasets. By integrating complementary regulatory evidence into a unified framework, mV2G provides an accessible resource for interpreting the functional and phenotypic impact of genomic variation in relevant tissues for human diseases.

The multiomic Variant-to-Gene (mV2G, https://mv2g.hbliulab.org) is a comprehensive atlas that integrates diverse functional genomic evidence to prioritize tissue-specific variant-to-gene (V2G) associations. While genome-wide association studies (GWAS) have identified millions of associations between genetic variants and diseases, translating these findings into biological mechanisms remains challenging because >90% of variants reside in noncoding regions. Existing V2G resources provide complementary regulatory evidence but are fragmented and often lack tissue-specific interpretation. To address this challenge, we constructed the mV2G atlas by integrating 24 types of functional genomic evidence across 50 human tissues, including molecular quantitative trait loci, enhancer-gene predictions, three-dimensional chromatin interactions, and experimental validation. The atlas contains 188,634,118 evidence-supported V2G pairs involving 13,618,039 variants and 69,521 genes. We further developed a unified tissue-specific V2G prioritization framework and prioritized 1,530,420 high-confidence functional V2G pairs involving 1,131,316 unique variants, with 87% exhibiting tissue-specificity. The mV2G atlas provides searchable variant- and gene-centered interfaces, an interactive browser for visualizing variants, target genes, cis-regulatory elements, and chromatin states, as well as downloadable datasets. By integrating complementary regulatory evidence into a unified framework, mV2G provides an accessible resource for interpreting the functional and phenotypic impact of genomic variation in relevant tissues for human diseases.

Whole genome sequencing (WGS) studies play a pivotal role in studying the genetic underpinnings of human diseases and traits. High quality and reproducible variant calling is the cornerstone for the success of downstream analyses, including WGS association studies and polygenic risk prediction. This paper compares the data quality, performance, and concordance of two widely used WGS variant callers, the Genome Analysis Toolkit (GATK) and Variant Tool set that discovers short variants (VT), using 60 532 multi-ancestry whole genomes sequenced by the Centers for Common Disease Genomics (CCDGs) of the NHGRI Genome Sequencing Program. Our findings show that both QCed GATK and VT pipelines yield highly consistent and reliable called Single Nucleotide Variants (SNVs) in large-scale WGS studies, supporting their agreements in joint variants calling. However, the two pipelines exhibit greater discrepancies in calling insertions and deletions (INDELs).

Whole genome sequencing (WGS) studies in large biobanks provide an unprecedented opportunity to study the rare-variant (RV) effects on the natural history of human diseases by analyzing censored time-to-event (TTE) phenotypes, such as age at disease diagnosis, disease progression, and lifespan. Unlike existing methods developed for continuous and categorical phenotypes, rare-variant association tests (RVATs) for TTE phenotypes in large biobanks face several major challenges, including heavy censoring, cryptic relatedness, and population structure. We introduce GATE-STAAR (Genetic Analysis of Time-to-Event phenotypes via the variant-Set Test for Association using Annotation infoRmation), a powerful and computationally efficient frailty model framework for RVATs of TTE phenotypes in large biobanks. GATE-STAAR accounts for high censoring rates, cryptic relatedness, and population structure in large biobanks, while incorporating multifaceted variant functional annotations to improve power and result interpretability. We propose a rare-variant saddlepoint approximation method to effectively address heavy censoring in WGS TTE analysis. We demonstrate through extensive simulations that GATE-STAAR is powerful while maintaining proper control of type I error rates. We apply GATE-STAAR to analyze the WGS data of approximately 400,000 UK Biobank participants of white British ancestry across a variety of TTE phenotypes, and validate the findings using participants of European ancestry from the All of Us Research Program. These analyses uncover RV associations with age at diagnosis of a range of diseases.

While international efforts have characterized genetic variation in millions of individuals, the interplay of environmental, social, cultural and genetic factors is poorly understood for most worldwide populations. The province of Quebec in Canada has been the site of numerous genetic studies, often focusing on Mendelian diseases in founder sub-populations. Here, we analyze genomewide genotyped variation in 29,337 Quebec residents from the multi-ancestry population-based cohort CARTaGENE (CaG) who provided DNA samples. We also sequence the whole-genome of 2,173 CaG participants with four grandparents born in Canada (n = 1879), Haiti (n = 163) and Morocco (n = 131). We use this genetic information to gain insight into Quebec's demography and to help interpret the potential significance of variants identified in clinically important genes (e.g., SPG7 implicated in hereditary spastic paraplegia). We validate an imputation panel constructed by phasing the CaG whole-genome sequence data and find, using genome-wide association studies (GWAS) of 42 clinically relevant traits, that it increases the number of associated loci by ~7% when compared to results obtained after imputation with the larger TOPMed imputation panel. We provide allele frequency information and GWAS results through dedicated and publicly available websites. The genetic data, paired with phenotypic and environmental information, is available for global research use.

Understanding how rare genetic variants influence complex traits remains a major challenge, particularly when these variants lie in noncoding regions of the genome. The effects of variants within candidate cis-regulatory elements (cCREs) often depend on the cell type, making interpretation difficult. Here we introduce cellSTAAR, which integrates whole-genome sequencing data with single-cell assay for transposase-accessible chromatin using sequencing data to capture variability in chromatin accessibility across cell types via the construction of cell-type-specific functional annotations and regulatory elements. To reflect the uncertainty in cCRE–gene linking, cellSTAAR uses a comprehensive strategy to link cCREs to their target genes. We applied cellSTAAR to data from the Trans-Omics for Precision Medicine consortium (n ≈ 60,000) and replicated our findings using the UK Biobank (n ≈ 190,000). Across four lipid traits, cellSTAAR improved the detection of biologically meaningful associations and enhanced biological interpretability. These results demonstrate the potential of cell-type-aware approaches to boost discovery in rare variant whole-genome sequencing association studies.

The Functional Annotation of Variants Online Resource (FAVOR), http://favor.genohub.org, is a whole genome variant annotation database and portal that provides comprehensive variant functional annotations of all possible variants across the genome. It can facilitate the analysis of whole-genome sequencing studies, support the interpretation of variant functional impacts, and help prioritize causal variants of diseases or traits. To support the growing popularity and expand the scope of FAVOR, we present here a substantial platform update. The new release features dramatically expanded annotations, a completely redesigned infrastructure powered by a newly implemented application programming interface (FAVOR-API), and a revamped web interface with advanced data-visualization capabilities and enhanced query performance. Key expansions include much more comprehensive variant annotations, including global, tissue- and cell-type–specific variant annotations; gene and protein annotations; support for both hg38 and hg19 reference genomes; and an interactive genome-browser for visualization of multi-faceted variant annotations. The updated platform also includes FAVOR-GPT, a large language model-powered interface for navigating the FAVOR database and interpreting results. FAVOR continues to evolve to keep pace with advances in research on interpreting the functional and phenotypic impact of genomic variation.

Obstructive sleep apnea (OSA) is a multifactorial sleep disorder characterized by a strong genetic basis. Excessive daytime sleepiness (EDS) is a symptom that is reported by a subset of OSA patients, persisting even after treatment with continuous positive airway pressure (CPAP). It is recognized as a clinical subtype underlying OSA carrying alarming heightened cardiovascular risk. Thus, conceptualizing EDS as an exposure variable, we sought to investigate EDS’s influence on genetic variation linked to apnea-hypopnea index (AHI), a diagnostic measure of OSA severity. This study serves as the first large-scale genome-wide gene x environment interaction analysis for AHI, investigating the interplay between its genetic markers and EDS across and within specific sex. Our work pools together whole genome sequencing data from seven cohorts, enabling a diverse dataset (four population backgrounds) of over 11,500 samples. Among the total 16 discovered genetic targets with interaction evidence with EDS, eight are previously unreported for OSA, including CCDC3, MARCHF1, and MED31 identified in all sexes; TMEM26, CPSF4L, and PI4K2B identified in males; and RAP1GAP and YY1 identified in females. We discuss connections to insulin resistance, thiamine deficiency, and resveratrol use that may be worthy of therapeutic consideration for excessively sleepy OSA patients.

R-loop-triggered collateral single-stranded DNA (ssDNA) nuclease activity within Class 1 Type I CRISPR-Cas systems holds immense potential for nucleic acid detection. However, the hyperactive ssDNase activity of Cas3 introduces unwanted noise and false-positive results. In this study, we identified a novel Type I-A Cas3 variant derived from Thermococcus siculi, which remains in an auto-inhibited state until it is triggered by Cascade complex and R-loop formation. This Type I-A CRISPR-Cas3 system not only exhibits an expanded protospacer adjacent motif (PAM) recognition capability but also demonstrates remarkable intolerance towards mismatched sequences. Furthermore, it exhibits dual activation modes—responding to both DNA and RNA targets. The culmination of our research efforts has led to the development of the Hyper-Active-Verification Establishment (HAVE, 惠父). This innovation enables swift and precise human papillomavirus (HPV) diagnosis in clinical samples, providing a robust molecular diagnostic tool based on the Type I-A CRISPR-Cas3 system. Our findings contribute to understanding type I-A CRISPR-Cas3 system regulation and facilitate the creation of advanced diagnostic solutions with broad clinical applicability.